Pharmedic Pharmaceutical Medicinal Joint Stock Company, commonly referred to as Pharmedic, is a prominent player in the pharmaceutical industry, headquartered in Vietnam. Established in 2003, the company has made significant strides in the development and distribution of high-quality medicinal products across various regions in Vietnam and beyond. Pharmedic focuses on the research, production, and marketing of pharmaceuticals, including prescription medications and over-the-counter products. Its commitment to innovation and quality has positioned it as a trusted name in the market, with a diverse portfolio that caters to a wide range of therapeutic areas. Notable achievements include certifications from international quality standards, underscoring its dedication to excellence in healthcare. With a strong market presence, Pharmedic continues to enhance its reputation as a leader in the pharmaceutical sector.
How does Pharmedic Pharmaceutical Medicinal Joint Stock Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pharmedic Pharmaceutical Medicinal Joint Stock Company's score of 21 is lower than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmedic Pharmaceutical Medicinal Joint Stock Company, headquartered in Vietnam, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Consequently, there are no documented Scope 1, 2, or 3 emissions to analyse. In terms of climate commitments, Pharmedic has not established any reduction targets or initiatives, nor have they made any pledges related to climate action. This lack of data suggests that the company may still be in the early stages of developing a comprehensive sustainability strategy. As the pharmaceutical industry increasingly prioritises environmental responsibility, Pharmedic's future climate commitments will be crucial for aligning with industry standards and expectations. Without specific emissions data or reduction targets, the company may face challenges in demonstrating its commitment to reducing its carbon footprint and contributing to global climate goals.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pharmedic Pharmaceutical Medicinal Joint Stock Company has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
